Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor News
Share Price / Index
January 06, 2026
Not intended for U.S. and UK Media
Bayer receives Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for patients with HER2-mutant non-small cell lung cancer
December 22, 2025
Not intended for U.S. and UK Media
Finerenone approved in Japan for treatment of patients with chronic heart failure
December 12, 2025
Not intended for U.S. and UK Media
Aflibercept 8 mg recommended for EU approval for third retinal indication
Discover More
